Suchergebnisse - "Seyedkazemi, Sareh"

PubPharm (4)

1

Low Incidence and Brief Duration of Gastrointestinal Adverse Events with Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Over 96 Weeks : Post hoc Analyses of AMBER and EMERALD

enthalten in: Journal of the International Association of Providers of AIDS Care | 2022

von Dunn, K. | Baugh, B. | Bejou, N. | +4

2

Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection : a DIAMOND subgroup analysis

enthalten in: HIV research & clinical practice | 2021

von Dunn, K. | Rogers, R. | Simonson, R. | +5

3

Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection

enthalten in: HIV research & clinical practice | 2020

von Lathouwers, E. | Seyedkazemi, S. | Luo, D. | +3

4

HIV-1 resistance rarely observed in patients using darunavir once-daily regimens across clinical studies

enthalten in: HIV clinical trials | 2017

von Lathouwers, E. | Wong, E. | Luo, D. | +3

1
[1]